Degenerative Disc Disease Pipeline 2025: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Mesoblast, DiscGenics, Biosplice Therapeutics, BIOPHARM GmbH, Yuhan, Histogen, Boehringer Ingelheim, SpineOvations, Spine B

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Degenerative Disc Disease pipeline constitutes 15+ key companies continuously working towards developing 15+ Degenerative Disc Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Degenerative Disc Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

"Degenerative Disc Disease Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Degenerative Disc Disease Market.

Some of the key takeaways from the Degenerative Disc Disease Pipeline Report: https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Degenerative Disc Disease treatment therapies with a considerable amount of success over the years.
• Degenerative Disc Disease companies working in the treatment market are Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast, Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes, Inc., DiscGenics, Kuros Biosciences, BioRestorative Therapies, Angitia Biopharmaceuticals, and others, are developing therapies for the Degenerative Disc Disease treatment
• Emerging Degenerative Disc Disease therapies in the different phases of clinical trials are- SB-01, BRTX-100, Rexlemestrocel-L, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, BRTX-100, AGA111, and others are expected to have a significant impact on the Degenerative Disc Disease market in the coming years.
• In April 2025, DiscGenics, Inc., a privately owned, late-stage clinical biopharmaceutical company focused on developing allogeneic, cell-based regenerative therapies for musculoskeletal conditions, announced that its double-blind, peer-reviewed study titled "Allogeneic Disc Progenitor Cells Safely Increase Disc Volume and Improve Pain, Disability, and Quality of Life in Patients With Lumbar Disc Degeneration-Results of an FDA-Approved Biologic Therapy Randomized Clinical Trial," has been recognized as one of the top three most impactful articles published in the International Journal of Spine Surgery (IJSS) in 2024.
• In March 2025, Discure Technologies, a clinical-stage medical device company focused on innovative solutions for degenerative disc disease and other orthopedic conditions, announced its acceptance into the U.S. Food and Drug Administration's (FDA) Total Product Life Cycle (TPLC) Advisory Program (TAP). This inclusion is expected to accelerate patient access to the company's bioelectronic implant, the Discure System, which was previously granted Breakthrough Device designation by the FDA.
• In September 2024, Spine BioPharma Inc.-a company developing non opioid, non surgical therapies for degenerative disc disease-has finished enrolling patients in its U.S. Phase 3 trial of SB 01 for Injection. The MODEL study (MOderate-Severe Degenerative Disc Disease Evaluation of the Lumbar Spine) recruited 417 participants over two years at 30 research centers nationwide. SB 01 is the first intradiscal drug therapy to advance to Phase 3 testing for chronic low back pain and associated functional loss caused by degenerative disc disease.

Degenerative Disc Disease Overview
Degenerative Disc Disease (DDD) is a condition where the intervertebral discs-cushion-like structures between the spine's vertebrae-gradually lose hydration, flexibility, and height due to aging or wear and tear. This degeneration can lead to pain, stiffness, reduced mobility, and sometimes nerve compression, causing symptoms like numbness or weakness in the limbs. DDD most commonly affects the cervical (neck) and lumbar (lower back) spine. It is not technically a disease but a natural part of aging for many people. Treatment options include physical therapy, pain management, lifestyle changes, and in severe cases, surgical intervention like spinal fusion or disc replacement.

Get a Free Sample PDF Report to know more about Degenerative Disc Disease Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Degenerative Disc Disease Drugs Under Different Phases of Clinical Development Include:
• SB-01: Spine BioPharma, Inc.
• BRTX-100: BioRestorative Therapies
• Rexlemestrocel-L: Mesoblast, Ltd.
• Lorecivivint: Biosplice Therapeutics
• CWT 002: Causeway Therapeutics
• AMG0103: AnGes, Inc.
• IDCT: DiscGenics
• KUR 113: Kuros Biosciences
• BRTX-100: BioRestorative Therapies
• AGA111: Angitia Biopharmaceuticals

Degenerative Disc Disease Route of Administration
Degenerative Disc Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Degenerative Disc Disease Molecule Type
Degenerative Disc Disease Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Degenerative Disc Disease Pipeline Therapeutics Assessment
• Degenerative Disc Disease Assessment by Product Type
• Degenerative Disc Disease By Stage and Product Type
• Degenerative Disc Disease Assessment by Route of Administration
• Degenerative Disc Disease By Stage and Route of Administration
• Degenerative Disc Disease Assessment by Molecule Type
• Degenerative Disc Disease by Stage and Molecule Type

DelveInsight's Degenerative Disc Disease Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Degenerative Disc Disease product details are provided in the report. Download the Degenerative Disc Disease pipeline report to learn more about the emerging Degenerative Disc Disease therapies
https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Degenerative Disc Disease Therapeutics Market include:
Key companies developing therapies for Degenerative Disc Disease are - Mesoblast, Ltd., BioRestorative Therapies, DiscGenics, Inc., Biosplice Therapeutics, Boehringer Ingelheim, SpineOvations, BIOPHARM GmbH, Yuhan, Histogen Inc., Spine BioPharma, Inc., Angitia Biopharmaceuticals, Notogen, AnGes, Inc., FibroGenesis, Genequine Biotherapeutics, Causeway Therapeutics, and others

Degenerative Disc Disease Pipeline Analysis:
The Degenerative Disc Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Degenerative Disc Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Degenerative Disc Disease Treatment.
• Degenerative Disc Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Degenerative Disc Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Degenerative Disc Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Degenerative Disc Disease drugs and therapies
https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Degenerative Disc Disease Pipeline Market Drivers
• Increase in the prevalence of Degenerative Disc Disease, increasing Research and Development activities are some of the important factors that are fueling the Degenerative Disc Disease Market.

Degenerative Disc Disease Pipeline Market Barriers
• However, cost associated with the treatment, poor patient compliance and other factors are creating obstacles in the Degenerative Disc Disease Market growth.

Scope of Degenerative Disc Disease Pipeline Drug Insight
• Coverage: Global
• Key Degenerative Disc Disease Companies: Spine BioPharma, Inc., BioRestorative Therapies, Mesoblast, Ltd., Biosplice Therapeutics, Causeway Therapeutics, AnGes, Inc., DiscGenics, Kuros Biosciences, BioRestorative Therapies, Angitia Biopharmaceuticals, and others
• Key Degenerative Disc Disease Therapies: SB-01, BRTX-100, Rexlemestrocel-L, Lorecivivint, CWT 002, AMG0103, IDCT, KUR 113, BRTX-100, AGA111, and others
• Degenerative Disc Disease Therapeutic Assessment: Degenerative Disc Disease current marketed and Degenerative Disc Disease emerging therapies
• Degenerative Disc Disease Market Dynamics: Degenerative Disc Disease market drivers and Degenerative Disc Disease market barriers

Request for Sample PDF Report for Degenerative Disc Disease Pipeline Assessment and clinical trials
https://www.delveinsight.com/sample-request/degenerative-disc-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Degenerative Disc Disease Report Introduction
2. Degenerative Disc Disease Executive Summary
3. Degenerative Disc Disease Overview
4. Degenerative Disc Disease- Analytical Perspective In-depth Commercial Assessment
5. Degenerative Disc Disease Pipeline Therapeutics
6. Degenerative Disc Disease Late Stage Products (Phase II/III)
7. Degenerative Disc Disease Mid Stage Products (Phase II)
8. Degenerative Disc Disease Early Stage Products (Phase I)
9. Degenerative Disc Disease Preclinical Stage Products
10. Degenerative Disc Disease Therapeutics Assessment
11. Degenerative Disc Disease Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Degenerative Disc Disease Key Companies
14. Degenerative Disc Disease Key Products
15. Degenerative Disc Disease Unmet Needs
16 . Degenerative Disc Disease Market Drivers and Barriers
17. Degenerative Disc Disease Future Perspectives and Conclusion
18. Degenerative Disc Disease Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Degenerative Disc Disease Market https://www.delveinsight.com/report-store/degenerative-disc-disease-ddd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Degenerative Disc DiseaseMarket Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Degenerative Disc Disease Epidemiology https://www.delveinsight.com/report-store/degenerative-disc-disease-ddd-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Degenerative Disc Disease Epidemiology Forecast to 2034' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:
• Post Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• HiPost Menopausal Osteoporosis Market: https://www.delveinsight.com/report-store/post-menopausal-osteoporosis-pipeline-insight
• Hip Replacement Devices Market: https://www.delveinsight.com/report-store/hip-reconstruction-devices-market
• Amblyopia Market: https://www.delveinsight.com/report-store/amblyopia-market
• Type 2 Diabetes Market: https://www.delveinsight.com/report-store/diabetes-market
• Parp Poly Adp-ribose Polymerase Inhibitor Market: https://www.delveinsight.com/report-store/poly-adp-ribose-polymerase-1-parp-inhibitor-pipeline-insight

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.